Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2025)

Journey Medical's Asset Writedowns and Impairment history spans 6 years, with the latest figure at -$41000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 86.64% year-over-year to -$41000.0, compared with a TTM value of -$211000.0 through Dec 2025, down 140.89%, and an annual FY2025 reading of -$211000.0, down 140.89% over the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was -$41000.0 at Journey Medical, down from $76000.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $3.1 million in Q2 2023, with the low at -$2.7 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 5 years is $188350.0, with a median of $62500.0 recorded in 2021.
  • Biggest YoY gain for Asset Writedowns and Impairment was 10038.71% in 2023; the steepest drop was 1088.32% in 2023.
  • Tracing DERM's Asset Writedowns and Impairment over 5 years: stood at $115000.0 in 2021, then skyrocketed by 138.26% to $274000.0 in 2022, then tumbled by 1088.32% to -$2.7 million in 2023, then skyrocketed by 88.66% to -$307000.0 in 2024, then soared by 86.64% to -$41000.0 in 2025.
  • Per Business Quant, the three most recent readings for DERM's Asset Writedowns and Impairment are -$41000.0 (Q4 2025), $76000.0 (Q3 2025), and -$441000.0 (Q2 2025).